Compare SLDP & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | LYEL |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | 230 | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.7M | 490.1M |
| IPO Year | N/A | 2021 |
| Metric | SLDP | LYEL |
|---|---|---|
| Price | $2.91 | $20.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.00 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 3.2M | 82.2K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.90 | $17,438.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.68 | $0.39 |
| 52 Week High | $8.86 | $45.00 |
| Indicator | SLDP | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 48.33 |
| Support Level | N/A | $16.20 |
| Resistance Level | $3.22 | $27.30 |
| Average True Range (ATR) | 0.16 | 1.83 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 22.86 | 73.02 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.